1
|
Buczyńska A, Sidorkiewicz I, Rogucki M, Siewko K, Adamska A, Kościuszko M, Maliszewska K, Kozłowska G, Szumowski P, Myśliwiec J, Dzięcioł J, Krętowski A, Popławska-Kita A. Oxidative stress and radioiodine treatment of differentiated thyroid cancer. Sci Rep 2021; 11:17126. [PMID: 34429481 PMCID: PMC8384841 DOI: 10.1038/s41598-021-96637-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 08/12/2021] [Indexed: 02/06/2023] Open
Abstract
It is hypothesized that the oxidative stress level in thyroid cancer patients is additionally upregulated by radioactive iodine (RAI) treatment, that may exert an important impact on future health concerns. In our study, we evaluated the oxidative stress level changes using the measurement of malondialdehyde (MDA) concentration in patients with differentiated thyroid cancer (DTC) undergoing RAI treatment. Considering the results obtained in the study group, the serum levels of MDA in DTC patients were significantly higher compared to the healthy subjects (p < 0.05). The MDA concentration was significantly higher on the third day after RAI (p < 0.001) and significantly lower one year after RAI (p < 0.05) in DTC patients compared to the baseline concentration. Moreover, the redox stabilization after RAI treatment in patients with DTC during a year-long observation was demonstrated. Accordingly, an increased oxidative stress impact on the related biochemical parameters reflecting the health conditions of the DTC patients was determined. Our study showed that increased oxidative stress reflected by MDA measurements in DTC patients is further enhanced by RAI, but this effect is no longer observed one year after the therapy.
Collapse
Affiliation(s)
- Angelika Buczyńska
- grid.48324.390000000122482838Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Iwona Sidorkiewicz
- grid.48324.390000000122482838Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Mariusz Rogucki
- grid.48324.390000000122482838Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Katarzyna Siewko
- grid.48324.390000000122482838Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Agnieszka Adamska
- grid.48324.390000000122482838Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Maria Kościuszko
- grid.48324.390000000122482838Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Katarzyna Maliszewska
- grid.48324.390000000122482838Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Gabryela Kozłowska
- grid.48324.390000000122482838Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Piotr Szumowski
- grid.48324.390000000122482838Department of Nuclear Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Janusz Myśliwiec
- grid.48324.390000000122482838Department of Nuclear Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Janusz Dzięcioł
- grid.48324.390000000122482838Department of Human Anatomy, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Adam Krętowski
- grid.48324.390000000122482838Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland ,grid.48324.390000000122482838Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Anna Popławska-Kita
- grid.48324.390000000122482838Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland
| |
Collapse
|
2
|
Sengoz T, Kilic-Toprak E, Yaylali O, Kilic-Erkek O, Ozdemir Y, Oymak B, Senol H, Yuksel D, Kucukatay V, Bor-Kucukatay M. Hemorheology and oxidative stress in patients with differentiated thyroid cancer following I-131 ablation/metastasis treatment. Clin Hemorheol Microcirc 2019; 74:209-221. [PMID: 31884456 DOI: 10.3233/ch-190717] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Although radioiodine theraphy (RAIT) is thought to affect blood cells and oxidative stress, hemorheological alterations following dose-dependent RAIT remains unknown. OBJECTIVE The aim of this study was to determine the effects of RAIT on hemorheological and oxidative stress parameters in patients with differentiated thyroid cancers (DTC). METHODS Totally 31 DTC patients (mean age 46.32±11.15 years) and 26 healthy controls (mean age 50.50±6.22 years) were included. Venous blood samples were collected from each patient before and after treatment (7th day, 1th month and 6th month). Erythrocyte aggregation-deformability and oxidative stress parameters were determined. p < 0.05 was considered as statistically significant. RESULTS Erythrocyte deformability of the patients determined at 16.87 and 30 Pascal were significantly lower than healthy individuals. Erythrocyte aggregation index (AI) of the patients was higher, whereas erythrocyte aggregation half-time (t½) was lower compared to control. Erythrocyte deformability values and AI were not significantly different from the pre- and post-radioiodine treatment groups. There was no statistically significant difference between the oxidative stress parameters before and after the treatment. CONCLUSIONS Patients were in a worse hemorheological condition compared to healthy individuals. After RAIT, RBC deformability and aggregation were not affected and no significant change in oxidative stress parameters was detected.
Collapse
Affiliation(s)
- Tarik Sengoz
- Pamukkale University, Medical Faculty, Department of Nuclear Medicine, Denizli, Turkey
| | - Emine Kilic-Toprak
- Pamukkale University, Medical Faculty, Department of Physiology, Denizli, Turkey
| | - Olga Yaylali
- Pamukkale University, Medical Faculty, Department of Nuclear Medicine, Denizli, Turkey
| | - Ozgen Kilic-Erkek
- Pamukkale University, Medical Faculty, Department of Physiology, Denizli, Turkey
| | - Yasin Ozdemir
- Pamukkale University, Medical Faculty, Department of Physiology, Denizli, Turkey
| | - Burak Oymak
- Pamukkale University, Medical Faculty, Department of Physiology, Denizli, Turkey
| | - Hande Senol
- Pamukkale University, Faculty of Medicine, Department of Biostatistics, Denizli, Turkey
| | - Dogangun Yuksel
- Pamukkale University, Medical Faculty, Department of Nuclear Medicine, Denizli, Turkey
| | - Vural Kucukatay
- Pamukkale University, Medical Faculty, Department of Physiology, Denizli, Turkey
| | - Melek Bor-Kucukatay
- Pamukkale University, Medical Faculty, Department of Physiology, Denizli, Turkey
| |
Collapse
|
3
|
Rosário PW, Batista KCS, Calsolari MR. Radioiodine-induced oxidative stress in patients with differentiated thyroid carcinoma and effect of supplementation with vitamins C and E and selenium (antioxidants). ARCHIVES OF ENDOCRINOLOGY AND METABOLISM 2016; 60:328-32. [PMID: 26910631 PMCID: PMC10118725 DOI: 10.1590/2359-3997000000128] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2015] [Accepted: 09/30/2015] [Indexed: 11/21/2022]
Abstract
OBJECTIVE The objective of this study, in addition to confirming that therapy with 131I causes oxidative stress, was to evaluate the effect of supplementation with vitamins C and E and selenium on this phenomenon by measuring plasma 8-epi-PGF2a, a marker of lipid peroxidation. SUBJECTS AND METHODS Forty patients with thyroid cancer submitted to thyroidectomy, who received 3.7 GBq 131I after levothyroxine withdrawal, were selected; 20 patients did not receive (control group) and 20 patients received (intervention group) daily supplementation consisting of 2000 mg vitamin C, 1000 mg vitamin E and 400 µg selenium for 21 days before 131I. Plasma 8-epi-PGF2a was measured immediately before and 2 and 7 days after 131I. RESULTS A significant increase in plasma 8-epi-PGF2a after 131I was observed in the two groups. The concentrations of 8-epi-PGF2α were significantly higher in the control group before and 2 and 7 days after 131I. The percentage of patients with elevated 8-epi-PGF2α was also significantly higher in the control group before and after 131I. Furthermore, the increase (percent) in 8-epi-PGF2α was significantly greater in the control group (average of 112.3% versus 56.3%). Only two patients (10%) reported side effects during supplementation. CONCLUSIONS Ablation with 131I causes oxidative stress which can be minimized by the use of antioxidants.
Collapse
Affiliation(s)
- Pedro Weslley Rosário
- Programa de Pós-Graduação, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brasil.,Serviço de Endocrinologia, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brasil
| | | | | |
Collapse
|
4
|
Noaparast Z, Hosseinimehr SJ. Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy. Future Oncol 2013; 9:1145-59. [DOI: 10.2217/fon.13.79] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Radioiodine 131 (131I) has been used worldwide for the ablation of remnant thyroidal tissue after surgery or as the first-line treatment for Graves’ disease. Although the use of 131I is becoming increasingly prevalent, there is evidence suggesting that this treatment is associated with side effects such as salivary gland dysfunction and an increased risk of leukemia. This article aims to review the potential use of radioprotective agents and the side effects induced by 131I therapy. Several synthetic and natural compounds have been investigated in preclinical and clinical studies. The protective agents reduced the toxicity of 131I, mainly in the salivary glands, and mitigated the genetic damage through different mechanisms. There are limited clinical studies evaluating the use of radioprotective agents in patients undergoing radioiodine therapy. However, lemon candies, lemon juice and sugarless chewing gum have been proposed to be beneficial for minimizing the side effects of radioiodine within the salivary glands.
Collapse
Affiliation(s)
- Zohreh Noaparast
- Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran
| | - Seyed Jalal Hosseinimehr
- Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
| |
Collapse
|